Effect of semaglutide on primary prevention of diabetic kidney disease in people with type 2 diabetes: A post hoc analysis of the SUSTAIN 6 randomized controlled trial.
semaglutide 對於 2 型糖尿病患者糖尿病腎病初級預防的影響:SUSTAIN 6 隨機對照試驗的事後分析。
Diabetes Obes Metab 2024-08-27
Comparison of societal guidance on perioperative management of glucagon-like peptide-1 receptor agonists: implications for clinical practice and future investigations.
胰高血糖素樣肽-1 受體激動劑圍手術管理的社會指導比較:對臨床實踐和未來研究的影響。
Can J Anaesth 2024-08-26
Effect of tirzepatide on the progression of coronary atherosclerosis using MDCT: Rationale and design of the Tirzepatide treatment on coronary atherosclerosis progression: The (T-PLAQUE) randomized-controlled trial design: tirzepatide and plaque.
tirzepatide 對冠狀動脈動脈粥樣硬化進展的影響:使用 MDCT 的理由與設計:Tirzepatide 對冠狀動脈動脈粥樣硬化進展的隨機對照試驗設計:tirzepatide 與斑塊。
Am Heart J 2024-08-26
Sodium-Glucose Cotransporter-2 Inhibitors, Dulaglutide, and Risk for Dementia : A Population-Based Cohort Study.
鈉-葡萄糖共轉運蛋白-2 抑制劑、Dulaglutide 與癡呆風險:一項基於人群的隊列研究。
Ann Intern Med 2024-08-26
Machine learning assessment of vildagliptin and linagliptin effectiveness in type 2 diabetes: Predictors of glycemic control.
機器學習評估 vildagliptin 和 linagliptin 在 2 型糖尿病中的有效性:血糖控制的預測因子。
PLoS One 2024-08-26
Sodium-Glucose Cotransporter-2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Discontinuation in Patients with CKD.
慢性腎病患者中鈉-葡萄糖共轉運蛋白-2抑制劑和類胰高血糖素肽-1受體激動劑的停用。
J Am Soc Nephrol 2024-08-26
The Efficacy of Pharmacotherapy in the Treatment of Obesity in Patients With Type 2 Diabetes: A Systematic Review.
2型糖尿病患者肥胖症藥物治療的療效:系統性回顧。
Cureus 2024-08-26